2023 |
In December 2023, Panacea Biotec unveils EasyFourPol vaccine in a big leap for child immunization.
In August 2023, US delegation led by the US Ambassador to India, Mr. Eric Garcetti, visited Panacea Biotec R&D Centre. They are presently developing the novel Ttetravalent Dengue Vaccine “DengiAll”.
In May 2023, Biological E and Panacea Biotec, will manufacture the only global nOPV2 vaccine developed by Indonesia’s BioFarma in India.
In May 2023, Serum Institute of India and Panacea Biotec apply for Expression of Interest for collaborative Phase-III clinical trials for indigenous manufacturers to the Indian Council of Medical Research’s (ICMR).
In March 2023, Panacea is scaling up the production of its vaccine portfolio, including EasySix, Tetanus, Pertussis. Hepatitis-B, Influenza, and Polio. EasySix, patent protected in 30 countries, is estimated to have the potential to serve a US$ 1 billion annual market by 2030. They want to increase the capacity to 50-70 million doses annually.
In January 2023, Panacea Biotec donates 125,000 doses of Easyfive-TT (a fully liquid Pentavalent vaccine) to the Ministry of Health, Republic of Cuba.
In January 2023, Panacea Biotec donated 125,000 doses of Easy-five TT, which is a fully liquid Pentavalent vaccine to Ministry of Health, Republic of Cuba for use in the National Health System.
|
2022 |
In October 2022, UNICEF and the Pan American Health Organization (PAHO) awarded Panacea Biotec long-term supply contracts totalling US$ 127.30 million for the provision of its WHO-prequalified fully liquid Pentavalent vaccination, Easyfive-TT® (DTwP-HepB-Hib).
In February 2022, Panacea Biotec sold its domestic formulations business to Mankind Pharma for Rs. 1,908 crore (US$ 252.85 million).
In February 2022, CEPI, THSTI, and Panacea Biotec partnered to develop broadly protective Betacoronavirus vaccines.
|
2021 |
In September 2021, Panacea Biotec Limited exported the first shipment of the second dose of the Sputnik V vaccine in India.
In May 2021, Panacea Biotec Limited started domestic production of Russia’s Sputnik V vaccine to combat coronavirus
|
2020 |
Panacea Biotec announced successful completion of Phase I/II study of its novel, Tetravalent recombinant chimeric Dengue candidate vaccine, DengiAll
Panacea Biotec and Refana collaborate to develop COVID-19 vaccine
Panacea transfers pharmaceuticals business to its wholly owned subsidiary ‘Panacea Biotec Pharma Limited’
|
2019 |
Launched ViLACT to treat uncontrolled Type-2 Diabetes Mellitus patients
IndiaRF announced investment worth US$ 144million in Panacea Biotec
|
2018 |
Partnered with Serum Institute of India to expand market access for the world's first fully liquid wP-based hexavalent vaccine, EasySix. It vaccinates children against DTwP, Hib, Hep. B and Polio
Inked tripartite agreement with Natco Pharma Limited and Breckenridge Pharmaceuticals Inc. to manufacture and supply of Azacitidine injection in the US market
|
2017 |
Panacea Biotec announced acceptance of its abbreviated new drug application (ANDA) for paclitaxel protein bound particles by the US FDA
Partnered with Technology Development Board (TDB), Govt. of India, regarding financial assistance for development and commercialisation of Dengue Tetravalent Vaccine
|
2014 |
Partnered with a leading pharmaceutical company (name undisclosed) to develop and supply an immunosuppressant generic product in the US
|
2013 |
Received WHO PQ for EasyFive TT
|
2012 |
Partnered with Kremers Urban for 11 High Barrier to Entry Generics and launched Tacrolimus Capsules in the US
|
2007 |
Partnered with Punjab University to develop new chemical entities
Signed an agreement with Family Vaccines to supply combination vaccines in the Philippines
Launched seven anti-cancer products, manufactured by a Mumbai-based company and sold under the brand name of Panacea Biotec
|
2006 |
Panacea Biotec partnered with Nederlands Vaccine Instituut under which the latter would supply bulk Inactivated Polio Vaccines (IPV), which will be used by the company in the manufacture of finished IPV and several IPV based combination vaccines
Collaborated with national research development corporation for technology transfer of foot and mouth disease vaccine, developed by Indian Veterinary Research Institute
|
2004 |
Collaborated with Cambridge Bio-stability, the UK, for thermo stable vaccines
Marketing Joint Venture with Chiron (now Novartis) Vaccines, the UK
|
2002 |
Recombinant vaccine production plant was commissioned
|
2001 |
Collaborated with a European MNC for R&D
|
1995 |
Established State -of the- art drug delivery R&D centre at Lalru
|
1993 |
Panacea Biotec Ltd. was formed with the merger of Panacea Drugs (P) Ltd. & Radicura Pharma
|
1988 |
Established a plant to produce vaccines at New Delhi, under the name of Radicura Pharma
|